Spinal Muscular Atrophy: Understanding the Genetic Disease Affecting BraziliansSpinal Muscular Atrophy (SMA) is a progressive genetic disease that destroys motor neurons, leading to severe muscle weakness and atrophy. Without early diagnosis and treatment, it can be fatal in the first years of life.
In Brazil, 2,074 people are currently living with the disease, with approximately 300 severe cases reported each year. The condition highlights the critical importance of early screening and access to modern therapies.
SMA is caused by a mutation in the SMN1 gene, which produces a protein essential for motor neuron survival. As motor neurons degenerate, muscles weaken progressively, affecting movement, breathing, and swallowing.
Recent advances in treatment, including gene therapy and medications like nusinersen and risdiplam, have significantly improved outcomes for patients when administered early. Newborn screening programs are increasingly being implemented to facilitate timely intervention.
Health authorities and patient advocacy groups continue to push for broader access to diagnosis and treatment across Brazil, aiming to reduce the burden of this devastating disease and improve quality of life for affected individuals and their families.
